Anavex Life Sciences Corp
Closed
SectorHealthcare
3.34 1.83
Overview
Share price change
24h
Min
3.2800000000000002
Max
3.39
Income | 4.1M -5.7M |
|---|---|
EPS | -0.06 |
Employees | 34 |
EBITDA | -821K -6.5M |
Next Earnings | 11 sie 2026 |
|---|
Market Cap | 42M 273M |
|---|---|
Previous open | 1.51 |
Previous close | 3.34 |
News Sentiment
By Acuity
86%
14%
321 / 340 Ranking in Healthcare
Anavex Life Sciences Corp Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Anavex Life Sciences Corp Forecast
Sentiment
By Acuity
321 / 340 Ranking in Healthcare
News Sentiment
Very Strong Bearish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Interest expense on debt
EBITDA
Operating profit
$
About Anavex Life Sciences Corp
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
